Zavodnick told Pharmaceutical Technology that Excellergy plans to initiate an ex-US Phase I study of its lead ECRI candidate, a monoclonal antibody, in Q1 2026, with the goal of being ready for Phase ...

Chintu Patel, Co-Founder and Co-CEO, explained Amneal is "building 2 state-of-the-art facilities" for GLP-1 production and progressing with a concentrated wave of complex generics launches, stating ...

Amneal Pharmaceuticals, Inc. ( AMRX) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Good morning and welcome to the Amneal Pharmaceuticals Third Quarter 2025 Earnings Call. I will now turn the ...

Advanz Pharma Holdco Limited (Advanz Pharma), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech, a ...

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; ...

Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ?? Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ?? Updated 2025 Full Year Guidan ...

Amneal Pharmaceuticals (AMRX) caught investors’ attention after announcing regulatory submissions in the U.S. and Europe for a biosimilar to XOLAIR. This move taps into a multibillion-dollar market ...

Amneal Pharmaceuticals recently announced the submission of a Biologics License Application to the U.S. FDA for a proposed biosimilar to XOLAIR®, a leading therapy with approximately US$4.1 billion in ...

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...

'KPop Demon Hunters' join Bad Bunny on 'SNL' 'SNL' cold open spoofs Pete Hegseth’s military meeting 'SNL' cold open mocks Pam Bondi's Senate hearing What’s the solution for someone trying to sober up, ...